IMD business school for management and leadership courses

Eli Lilly’s AI strategy is augmentation, leveraging generative and predictive models into chemists’ tools to speed molecule design, while algorithms optimize clinical trial design, site selection, and patient recruitment using genomics, imaging, and digital health data. AI is also used to automate regulatory writing, using GenAI to draft patient narratives and submission documents. In June 2024, Eli Lilly teamed with OpenAI to apply generative AI models towards antimicrobial resistance.  
 

The October 2024 appointment of Chief AI Officer Thomas Fuchs underscores Lilly’s enterprise-wide AI commitment. Lilly also prioritizes workforce development through platforms like Lilly U, ELEVATE, and the Lilly Data & Analytics Institute, offering multilingual AI training and scenario-based simulations to ensure widespread AI fluency.